Literature DB >> 22632736

Patient comprehension and attitudes toward maintenance chemotherapy for lung cancer.

David E Gerber1, Heidi A Hamann, Drew W Rasco, Sharon Woodruff, Simon J Craddock Lee.   

Abstract

OBJECTIVE: Maintenance chemotherapy is a recently approved approach to the treatment of advanced non-small cell lung cancer (NSCLC). We sought to gain insight into patients' perceptions of maintenance chemotherapy using qualitative methods.
METHODS: We conducted thematic content analysis of focus groups at a freestanding cancer center and at an associated safety-net county hospital. Patients with advanced NSCLC who had started but not yet completed first-line platinum doublet chemotherapy were provided visual and written explanations of maintenance chemotherapy before being guided in group discussion.
RESULTS: Key themes to emerge for consideration of maintenance chemotherapy included: (1) survival benefits, disease control, and "buying time"; (2) the importance of "doing something"; (3) quality of life concerns; (4) the role of provider opinion/preference; and (5) the importance of logistics.
CONCLUSIONS: Patients undergoing first-line chemotherapy for advanced NSCLC were able to understand the concept of maintenance chemotherapy, distinguish it from traditional treatment paradigms, identify pros and cons of this approach, and convey reasons for considering it. PRACTICE IMPLICATIONS: Advances in oncology care that alter therapy modalities and delivery may significantly impact patient perceptions and treatment experiences. Clinical team members may wish to elicit treatment preferences of first-line patients through clinical discussion that anticipate these considerations.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22632736      PMCID: PMC3443304          DOI: 10.1016/j.pec.2012.04.013

Source DB:  PubMed          Journal:  Patient Educ Couns        ISSN: 0738-3991


  24 in total

Review 1.  Maintenance therapy in advanced non-small cell lung cancer: current status and future implications.

Authors:  Thomas E Stinchcombe; Mark A Socinski
Journal:  J Thorac Oncol       Date:  2011-01       Impact factor: 15.609

2.  Patients rate physician communication about lung cancer.

Authors:  Judith E Nelson; Elizabeth B Gay; Andrew R Berman; Charles A Powell; John Salazar-Schicchi; Juan P Wisnivesky
Journal:  Cancer       Date:  2011-04-14       Impact factor: 6.860

3.  Rituximab maintenance therapy for follicular lymphoma.

Authors:  Ian Haines
Journal:  Lancet       Date:  2011-04-02       Impact factor: 79.321

4.  Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer.

Authors:  Steven B Zeliadt; Scott D Ramsey; David F Penson; Ingrid J Hall; Donatus U Ekwueme; Leonard Stroud; Judith W Lee
Journal:  Cancer       Date:  2006-05-01       Impact factor: 6.860

Review 5.  Rigour and qualitative research.

Authors:  N Mays; C Pope
Journal:  BMJ       Date:  1995-07-08

6.  Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

Authors:  Gilles Salles; John Francis Seymour; Fritz Offner; Armando López-Guillermo; David Belada; Luc Xerri; Pierre Feugier; Réda Bouabdallah; John Vincent Catalano; Pauline Brice; Dolores Caballero; Corinne Haioun; Lars Moller Pedersen; Alain Delmer; David Simpson; Sirpa Leppa; Pierre Soubeyran; Anton Hagenbeek; Olivier Casasnovas; Tanin Intragumtornchai; Christophe Fermé; Maria Gomes da Silva; Catherine Sebban; Andrew Lister; Jane A Estell; Gustavo Milone; Anne Sonet; Myriam Mendila; Bertrand Coiffier; Hervé Tilly
Journal:  Lancet       Date:  2010-12-20       Impact factor: 79.321

7.  Treatment decisions for localized prostate cancer: asking men what's important.

Authors:  E S Holmboe; J Concato
Journal:  J Gen Intern Med       Date:  2000-10       Impact factor: 5.128

8.  Is 'watchful waiting' a real choice for men with prostate cancer? A qualitative study.

Authors:  A Chapple; S Ziebland; A Herxheimer; A McPherson; S Shepperd; R Miller
Journal:  BJU Int       Date:  2002-08       Impact factor: 5.588

9.  Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews.

Authors:  G Silvestri; R Pritchard; H G Welch
Journal:  BMJ       Date:  1998-09-19

10.  Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.

Authors:  Maurice Pérol; Christos Chouaid; David Pérol; Fabrice Barlési; Radj Gervais; Virginie Westeel; Jacky Crequit; Hervé Léna; Alain Vergnenègre; Gérard Zalcman; Isabelle Monnet; Hervé Le Caer; Pierre Fournel; Lionel Falchero; Michel Poudenx; Fabien Vaylet; Céline Ségura-Ferlay; Mojgan Devouassoux-Shisheboran; Miquel Taron; Bernard Milleron
Journal:  J Clin Oncol       Date:  2012-09-04       Impact factor: 44.544

View more
  9 in total

1.  Stigma among patients with lung cancer: a patient-reported measurement model.

Authors:  Heidi A Hamann; Jamie S Ostroff; Emily G Marks; David E Gerber; Joan H Schiller; Simon J Craddock Lee
Journal:  Psychooncology       Date:  2013-10-03       Impact factor: 3.894

Review 2.  Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea.

Authors:  David E Gerber; Joan H Schiller
Journal:  J Clin Oncol       Date:  2013-02-11       Impact factor: 44.544

3.  Elucidating patient-perceived role in "decision-making" among African Americans receiving lung cancer care through a county safety-net system.

Authors:  Simon Craddock Lee; Emily G Marks; Joanne M Sanders; Deborah J Wiebe
Journal:  J Cancer Surviv       Date:  2015-06-16       Impact factor: 4.442

4.  Oncology Nursing Perceptions of Patient Electronic Portal Use: A Qualitative Analysis.

Authors:  David E Gerber; Muhammad Shaalan Beg; Tobi Duncan; Mary Gill; Simon J Craddock Lee
Journal:  Oncol Nurs Forum       Date:  2017-03-01       Impact factor: 2.172

5.  Clinical decision-making and health-related quality of life during first-line and maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC): findings from a real-world setting.

Authors:  Monika Sztankay; Johannes Maria Giesinger; August Zabernigg; Elisabeth Krempler; Georg Pall; Wolfgang Hilbe; Otto Burghuber; Maximilian Hochmair; Gerhard Rumpold; Stephan Doering; Bernhard Holzner
Journal:  BMC Cancer       Date:  2017-08-23       Impact factor: 4.430

6.  Methodological Aspects of Focus Groups in Health Research: Results of Qualitative Interviews With Focus Group Moderators.

Authors:  Anja P Tausch; Natalja Menold
Journal:  Glob Qual Nurs Res       Date:  2016-03-14

7.  Quality of life versus length of life considerations in cancer patients: A systematic literature review.

Authors:  Anne Shrestha; Charlene Martin; Maria Burton; Stephen Walters; Karen Collins; Lynda Wyld
Journal:  Psychooncology       Date:  2019-05-15       Impact factor: 3.894

8.  Differences in Lung Cancer Treatment Preferences Among Oncologists, Patients and Family Members: A Semi-Structured Qualitative Study in China.

Authors:  Xiaoning He; Mengqian Zhang; Jing Wu; Song Xu; Xiangli Jiang; Ziping Wang; Shucai Zhang; Feng Xie
Journal:  Patient Prefer Adherence       Date:  2021-04-15       Impact factor: 2.711

9.  Quality of life during chemotherapy in lung cancer patients: results across different treatment lines.

Authors:  L M Wintner; J M Giesinger; A Zabernigg; M Sztankay; V Meraner; G Pall; W Hilbe; B Holzner
Journal:  Br J Cancer       Date:  2013-10-03       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.